While the O'Sullivan et al. study showed that foveal differentiation is potentially arrested at birth and changes little postnatally (15), this difference in the inner retinal thickness at the fovea after treatment for ROP may be attributed to the difference in vascular endothelial growth factor (VEGF) expression between anti-VEGF therapies like bevacizumab vs. laser photocoagulation (13). This evidence concerns the gene VEGFA and retinopathy of prematurity.